- Home
- App Analytics
- ACMO
- ACMO Vs. Oncoblast
ACMO vs Oncoblast Usage & Stats
Sidney Kimmel Cancer Center – Jefferson Health offers Advanced Certification Program in Molecular Oncology (ACMO), a case based, self-learning, interactive certification course on molecular oncology, in association with ROCHE and BioQuest Solutions. These online modules help equip community Oncologists/Pathologists in the country with the subject matter expertise and methods of genomic/personalized medicine in order enhance their knowledge and skills and bring a desired change their behaviours from protocol based to individualized patient care.
- Apple App Store
- Free
- Education
Store Rank
- -
The OncoBlast app, created by the Binaytara Foundation, offers a unique gaming experience for hematology and oncology providers. This app allows medical professionals in hematology and oncology to engage in educational games, enabling them to earn continuing education credits while playing. OncoBlast is available at no cost and provides interactive, real-time feedback to enhance learning experiences for providers.
The Binaytara Foundation is a non-profit organization dedicated to improving healthcare outcomes through advocacy, education, and innovation. Founded with a vision to create a significant impact in the healthcare sector, the foundation focuses on addressing gaps in medical knowledge and practice, especially in the fields of hematology and oncology. Their commitment to education and training extends beyond traditional methods, embracing technology and interactive platforms to reach a broader audience of healthcare professionals. This app, Oncoblast, takes us one step closer towards this commitment.
- Apple App Store
- Free
- Education
Store Rank
- -
ACMO vs. Oncoblast ranking comparison
Compare ACMO ranking trend in the past 28 days vs. Oncoblast
Rank
No Data Available
ACMO vs. Oncoblast ranking by country comparison
Compare ACMO ranking trend in the past 28 days vs. Oncoblast
No Data to Display
Compare to any site with our free trial
ACMO VS.
Oncoblast
December 19, 2024